ACS chemical neuroscience molecule spotlight on dimebon

Research output: Contribution to journalShort surveypeer-review

8 Scopus citations

Abstract

Dimebon (latrepirdine) is an antihistamine drug that has been used clinically in Russia since the early 1980s and is being studied jointly by Pfizer and Medivation for patients with Alzheimer's disease. The results from a pivotal Phase 3 clinical trial (CONNECTION) showed that Dimebon (latrepirdine) failed to meet its coprimary or secondary efficacy end points.

Original languageEnglish (US)
Pages (from-to)587-588
Number of pages2
JournalACS Chemical Neuroscience
Volume1
Issue number9
DOIs
StatePublished - Sep 15 2010

Keywords

  • AD
  • Alzheimer's Disease
  • Dimebon
  • Neurodegeneration
  • clinical trials

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Fingerprint Dive into the research topics of 'ACS chemical neuroscience molecule spotlight on dimebon'. Together they form a unique fingerprint.

Cite this